Gradient Health, Inc announces Partnership with Rhisa
RALEIGH, N.C. and PARIS, France, Mar. 13, 2023 – Medical technology companies Rhisa and Gradient Health join forces to accelerate healthcare innovation by providing a new scale of diverse data to researchers from around the world.
Artificial intelligence (AI) has the potential to revolutionize medical technology, however its effectiveness can be hampered by using small, unrepresentative training datasets. This issue is also warranting significant attention from regulators, meaning developers now need to be sure their AI products have been trained on sufficiently diverse datasets before they can secure FDA or CE clearances.
Spanning two continents, this collaboration means patients across Europe and North America will be able to benefit from new AI-powered medical technologies. Furthermore, researchers in these regions can now access compliant data quickly and securely.
Pierre Campredon, CEO of Rhisa said “Working with Gradient is an obvious direction for Rhisa as it multiplies the value creation for entire healthcare ecosytem. Furthermore, our mutual teams are fully supporting the mission driving Rhisa from day one : accelerating medical innovation with highly qualified data.”
Josh Miller, CEO of Gradient Health said “We’re thrilled to announce our collaboration with Rhisa. It’s great news for our clients and by extension the patients that will benefit from their technologies in the US and Europe.”
Rhisa is a European medtech company headquartered in Paris, France. They are developing the most efficient medical imaging European data platform while being the first and only company to have obtained GPDR clearance for its medical imaging data anonymization process and algorithms.
Rhisa accelerate medical innovation providing highly qualified data and platform for medical innovation and research purposes.
Gradient Health Team
Gradient Health is a medical technology company headquartered in Raleigh, North Carolina.
We provide instant access to the medical images needed to train and validate technologies, getting more equitable innovations to market, faster. We were founded to power better medical research by accelerating AI development.